Association of Aspirin, Metformin, and Statin Use with Gastric Cancer Incidence and Mortality: A Nationwide Cohort Study

Mi Hee Cho[1], Tae Gon Yoo[2], Su-Min Jeong[3,4,5,6], and Dong Wook Shin[6,7,8]

ABSTRACT

Anticancer effects of aspirin, metformin, and statins against gastric cancer, one of the most common cancers in the world, have been reported. This retrospective cohort study aimed to investigate independent associations of aspirin, metformin, and statin use with gastric cancer incidence and mortality after adjustment for concomitant use of other drugs, using pooled cohort data extracted from the Korean National Health Insurance claim database. Follow-up started on January 1, 2004 and ended at the date of gastric cancer diagnosis, death, or December 31, 2013. Exposures to drugs were defined as cumulative duration of use for aspirin and cumulative defined daily dose for metformin and statin, and were entered as time-dependent variables in Cox analysis models to avoid immortal time bias. Use of aspirin for longer than 182.5 and 547.5 days during 2-year interval was associated with reduced risks of gastric cancer incidence and mortality, respectively. Patients with diabetes were at higher risk of gastric cancer incidence and mortality than nondiabetic people, regardless of metformin treatment. However, metformin use among patients with diabetes was associated with a reduction in gastric cancer mortality in a dose-response manner. Statin use was also associated with a reduction of gastric cancer mortality in the general population, but not with gastric cancer incidence. In conclusion, long-term use of aspirin was independently associated with reduced incidence and mortality of gastric cancer in the general population, but metformin or statin use was only associated with a reduction of gastric cancer mortality in patients with diabetes and in the general population, respectively.

Prevention Relevance: Long-term use of aspirin was independently associated with reduced incidence and mortality of gastric cancer in the general population. Metformin or statin use, however, was only associated with a reduction of gastric cancer mortality in diabetic patients and in the general population in a dose-response manner, respectively.

Introduction

Although the incidence of gastric cancer has decreased over time, gastric cancer remains the fifth most frequently diagnosed

[1]Samsung C&T Medical Clinic, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Jongno-gu, Seoul, Republic of Korea (South). [2]Department of Family Medicine, Hongseong Medical Center, Hongseong-gun, Chungcheongnam-do, Republic of Korea (South). [3]Department of Family Medicine, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Gwanak-gu, Seoul, Republic of Korea (South). [4]Department of Family Medicine, Seoul National University Health Service Center, Gwanak-gu, Seoul, Republic of Korea (South). [5]Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, Massachusetts. [6]Department of Family Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Jongno-gu, Seoul, Republic of Korea (South). [7]Supportive Care Center, Samsung Comprehensive Cancer Center, Gangnam-gu, Seoul, Republic of Korea (South). [8]Department of Digital Health, SAIHST, Sungkyunkwan University, Jongno-gu, Seoul, Republic of Korea (South).

Corresponding Author: Dong Wook Shin, Samsung Medical Center, Gangnam-gu, Seoul 06351, Republic of Korea (South). Phone: 822-6190-5252; Fax: 822-3410-2459; E-mail: dwshin.md@gmail.com

cancer worldwide, responsible for more than 1,000,000 new patients with cancer, and was the third leading cause of cancer-related death in 2018 (1). Asian countries have the highest incident rate of gastric cancer (2). In Korea, patients with newly diagnosed gastric cancer numbered 229,180 in 2016 and a total of 78,194 patients died because of gastric cancer (3).

Cardiovascular disease is a major health problem contributing to one-third of deaths worldwide (4). A number of shared risk factors between cardiovascular disease and cancer have been reported, suggesting biological mechanisms common to cardiovascular disease and cancer (5). Chronic inflammation, a key biological mechanism for both cardiovascular disease and cancer (6, 7), is induced by shared risk conditions, such as hyperglycemia, obesity, and smoking, so controlling cardiovascular disease risk factors may help reduce cancer risk (8).

Aspirin, metformin, and statins are commonly prescribed to treat cardiovascular disease and diabetes in clinical practice. Many previous studies have suggested the anticancer effects of aspirin (9–12), metformin (13–15), and statin (16, 17) in addition to their intended therapeutic effects. Multiple epidemiologic studies investigated cancer risk associated with use of aspirin (18–21), metformin (22, 23), or statin (24–26) for various cancers, including colorectal, esophageal, gastric, and breast cancer. Several studies reported that the incidence of gastric cancer was reduced with regular (27) and cumulative use (28) of

aspirin. In a recent meta-analysis, the pooled RR of gastric cancer with aspirin use was 0.75 [95% confidence interval (CI), 0.65–0.86; ref. 21]. Metformin use was also associated with lower incidence of gastric cancer among patients with diabetes when used on a regular, long-term basis (23, 29), and in a recent meta-analysis, the pooled risk of gastric cancer with metformin use in patients with diabetes was 0.76 (95% CI, 0.64–0.91) compared with non-metformin therapies (30). Statin use was also related to lower gastric cancer incidence in a dose-response manner in case–control studies (31, 32), and the pooled risk estimate was 0.68 (95% CI, 0.51–91) in a meta-analysis (33).

Aspirin, metformin, and statins are often prescribed concomitantly because cardiovascular disease, diabetes, and dyslipidemia are common metabolic diseases. Therefore, failure to adjust for concomitant use of other drugs to evaluate associations of aspirin, metformin, and statin use with gastric cancer incidence and mortality could lead to false conclusion. For example, if we assume that aspirin use reduces gastric cancer incidence and statin users are more likely to be prescribed aspirin than statin nonusers, then statin use might erroneously appear to be associated with lower gastric cancer risk if the data are not adjusted to account for aspirin use. However, most previous studies have not considered concomitant use of other medication (27–29) or have done so only crudely by implementing a dichotomized variable (i.e., use vs. nonuse; ref. 31). A previous aspirin study did not adjust for metformin or statin use (27) and a previous metformin study did not adjust for aspirin or statin use (29). Cardiovascular drug use that was crudely defined as a dichotomous variable (use vs. nonuse) or according to duration of use, cannot reflect amount taken per day (29, 31, 34, 35). In addition, many previous studies are limited by case–control design, which is subject to selection or recall bias (31, 32), and numbers of study subjects in these studies were not large enough to conclude a dose–response relationship between drugs and gastric cancer–related risks (31, 32, 35). Furthermore, few studies on the putative anticancer effects of cardiovascular drugs have included data regarding gastric cancer mortality (18, 23, 36).

Thus, in this population-based cohort study, our primary objective was to investigate independent associations of aspirin, metformin, and statin use with gastric cancer incidence and mortality in the general population, using adjustment of concomitant use of other medications, to determine the potential of these cardiovascular drugs as chemopreventive agents in clinical practice.

Materials and Methods

Data source and study population

The Korean National Health Insurance (KNHI) provides several sets of sample cohort data that are extracted from the claims database for research purposes; for this study, we pooled three cohorts to increase statistical power. First, the National Health Insurance Service (NHIS)-Senior Cohort was randomly selected to represent 10% of the Korean population aged ≥60 years in 2002 ($n = 558,147$). Second, the NHIS-Health Screening Cohort (NHIS-HealS) was randomly selected to

represent 10% of the Korean population ages 40–79 years in 2002 who received national health screening examinations during 2002–2003 ($n = 514,866$). Finally, the NHIS-National Sample Cohort (NHIS-NSC) comprised 2.2% of the all-age Korean population covered by the KNHI program in 2002 ($n = 1,025,340$). The design and use of these databases are described in detail elsewhere (37, 38).

As we used a 2-year interval to define drug exposure for time-dependent analysis (see below for details), we excluded patients who died from any cause ($n = 23,823$) or made claims for any cancer ($n = 55,529$) before January 1, 2004. People aged <20 years in 2002 ($n = 278,026$) were also excluded from the study. Finally, we identified 1,740,975 study participants drawn from the NHIS-Senior Cohort, NHIS-HealS, and NHIS-NSC databases (**Fig. 1**). Among them, 811,862 subjects participated in health screenings during 2002–2003, and these were classified as the screening subset population. Data for the health behaviors and health screening results of these individuals were included in this study. The study protocol was approved by the Institutional Review Board of Seoul National University Hospital [Jongno-gu, Seoul, Republic of Korea (South), IRB no.: E-1612-007-809]. Because of the anonymity of the NHIS data, the requirement for informed consent from individual subjects was waived.

Follow-up and case ascertainment

Gastric cancer incidence was determined using the registered gastric cancer diagnosis code (International Classification of Diseases-10 code C16) that matched the KNHI claims data for treatments (surgical operation, radiotherapy, or use of chemotherapeutic agents) for gastric cancer. Gastric cancer mortality data were obtained from the Korean National Death Registry. Follow-up started on January 1, 2004 (the index date) and ended at the date of gastric cancer diagnosis (incidence), death from gastric cancer (mortality), death from any other cause, or December 31, 2013, whichever came first.

Exposure to cardiovascular drugs (aspirin, metformin, and statins)

Cumulative use of cardiovascular drugs was analyzed within a 2-year latent period and was entered as a time-dependent variable in models to avoid immortal time bias (Supplementary Fig. S1). Time-dependent exposure to cardiovascular drugs was defined in two ways: (i) for aspirin, cumulative duration of use, defined as the total number of days of drug exposure and (ii) for metformin and statins, cumulative defined daily dose (cDDD), which uses the defined daily dose (DDD) system, a validated unit of drug consumption defined by the World Health Organization to standardize the dosage of drugs across multiple types (39). Because acetylsalicylic acid with any dose or frequency in a single day has independent strength for antiplatelet use, aspirin use for a day is equivalent to 1 DDD of aspirin. All aspirins prescribed as a cardiovascular drug in Korea are low-dose aspirin. The cumulative duration of aspirin use was categorized as never use, <182.5, 182.5–365.0, 365.0–547.5, and 547.5–730.0 days. The cDDD for metformin and statins represents the total dose of each drug prescribed during the

Figure 1.
Study participants. The final pooled cohort includes the (i) NHIS-Senior Cohort, (ii) NHIS-HealS Cohort, and (iii) NHIS-NSC.

study period and was categorized as never use, <182.5, 182.5–365.0, 365.0–547.5, and 547.5–730.0 cDDD-days.

Potential confounders

Data for potential confounders available from the KNHI claims database included sex, age, income level, Charlson comorbidity index (CCI), and metabolic risk factors, such as smoking status, alcohol consumption, body mass index (BMI), and history of hypertension. The study sample was grouped into 5-year age categories based on age in 2002. We used monthly insurance premiums as proxies for economic status because they are imposed according to income level in Korea.

Statistical analysis

Descriptive statistics were used to summarize baseline characteristics of the study population and cumulative duration of use (aspirin)/cDDD (metformin and statin). Cox proportional hazards models were used with time-dependent covariates for cardiovascular drug exposure. First, we assessed associations between the cumulative dose of each cardiovascular drug and the incidence or mortality of gastric cancer in separate analyses. Second, we performed the same Cox regression analyses with all cardiovascular drug use as covariates in one Cox model (the concurrent model). All models were adjusted for the following variables, measured during 2002–2003: (i) model 1 was adjusted for age, sex, income, and CCI and (ii) model 2 included the

same variables as model 1 and was additionally adjusted for BMI, smoking status, alcohol consumption, and hypertension using a screening subset population (about half of the study population who received national health screening examinations during 2002–2003). We also conducted subgroup analyses according to sex, age, BMI, smoking status, and alcohol consumption. All statistical analyses were conducted using STATA version 14.1 (StataCorp). All results were considered significant at two-sided $P < 0.05$.

Results

Baseline characteristics

Baseline sociodemographic characteristics, health behaviors, and medical conditions of the total study population and subgroups depending on use of aspirin, metformin, and statin are presented in **Table 1**. In the pooled cohort, ever-users of aspirin and statin comprised of 158,446 (9.10%) and 80,271 (4.61%) individuals, respectively. Patients with type 2 diabetes comprised of 113,208 (6.50%) individuals, and metformin ever-users numbered 62,801 (55.5%) individuals among patients with diabetes. **Table 2** shows the cumulative doses of aspirin, metformin, and statin for every 2 years during follow-up. As the total numbers of cardiovascular drug users increased, proportions of long-term users (for aspirin use ≥547.5 days and for metformin or statin use ≥547.5 cDDD-days) gradually increased over time (**Table 2**).

Use of cardiovascular drugs and gastric cancer incidence and mortality

Risks of gastric cancer incidence and mortality from separate analyses and concurrent analyses are presented in **Tables 3** and **4**, respectively. During the observation period, patients who were diagnosed with gastric cancer numbered 16,843 [incidence rate (IR), 103.83 per 10^5 person-year] in model 1 and 9,250 (IR, 118.84 per 10^5 person-year) in model 2 (**Table 3**). A total of 9,250 and 3,206 deaths related to gastric cancer were observed over the follow-up years in model 1 and model 2, respectively (**Table 3**).

Aspirin use for ≥182.5 days showed significant beneficial effects on gastric cancer incidence in the separate analysis (**Table 3**). Risks of gastric cancer mortality significantly decreased in people with aspirin use for ≥547.5 days [adjusted HR (aHR), 0.68; 95% CI, 0.63–0.74 in model 1 and aHR, 0.62; 95% CI, 0.54–0.72 in model 2) in the separate analysis (**Table 3**). Results were consistent after adjusting for cDDDs of metformin and statin use in the concurrent model (**Table 4**). P values for trend of gastric cancer incidence and mortality were <0.001 in both analytic models, suggesting dose-dependent relationships.

For metformin use, patients with diabetes were at higher risk of gastric cancer incidence than nondiabetic people, regardless of metformin treatment (**Table 3**). Metformin use among patients with diabetes did not show significant benefits on gastric cancer mortality compared with that in nondiabetic

people (**Table 3**). However, although there was no statistical significance, risk of gastric cancer mortality was reduced among patients with diabetes with metformin use for ≥547.5 cDDD-days (aHR, 0.82; 95% CI, 0.57–1.19 in model 1 and aHR, 0.67; 95% CI, 0.35–1.29 in model 2), even compared with that in nondiabetic people (**Table 3**). In the additional analysis with only patients with diabetes, gastric cancer mortality decreased with metformin use in a dose-response manner ($P_{trend} < 0.001$ in both models; **Table 5**). These results remained similar after adjustments for aspirin and statin use (**Table 4**).

Gastric cancer incidence was not associated with statin use in the general population (**Table 3**). On the other hand, gastric cancer mortality decreased in a dose-response manner in people even with statin use for <182.5 cDDD-days (aHR, 0.71; 95% CI, 0.64–0.78 in model 1 and aHR, 0.67; 95% CI, 0.35–1.29 in model 2; $P_{trend} < 0.001$ in both models; **Table 3**). While results were generally consistent after additional adjustments, estimate risk of gastric cancer mortality was attenuated in the concurrent analysis model (**Table 4**).

Subgroup analyses

Supplementary Tables show aHRs of gastric cancer incidence and mortality in subgroup analysis stratified by sex (Supplementary Table S1), age (Supplementary Table S2), BMI (Supplementary Table S3), smoking status (Supplementary Table S4), and alcohol consumption (Supplementary Table S5). Although statistical significance differed depending on drug, results of subgroup analysis showed consistent tendencies.

Discussion

In this population-based cohort study, we investigated independent associations of aspirin, statin, and metformin use with gastric cancer incidence and mortality in the general population after adjustment for concomitant use of other cardiovascular drugs. Long-term use of aspirin was independently associated with reduced incidence and mortality of gastric cancer in the general population. However, metformin use was positively associated with reduction of gastric cancer mortality only in patients with diabetes. Statin use was also associated with a reduced risk of gastric cancer mortality, but not with that of gastric cancer incidence, in the general population. Strengths of our study are (i) inclusion of a large representative sample (∼1.7 million) in a region with high gastric cancer incidence, which reduces selection bias and enhances statistical power, (ii) use of a reliable prescription database obtained through a compulsory, single, national insurance system and use of validated units of drug consumption, and (iii) simultaneous examination of common cardiovascular drugs in a single analytic model with adjustment for the effects of each drug.

Carcinogenesis of gastric cancer involves multiple factors (40), and several studies suggest that the cyclooxygenase-2 (COX-2) genes are one of the risk factors of gastric cancer (41). Because

Table 1. Baseline characteristics of the study population, classified by history of cardiovascular drug use during 2002–2003.

	Total	Aspirin			Metformin				Statin		
		Never user	Ever user	P	Non-DM	Never user	Ever user	P	Never user	Ever user	P
N (%)	1,740,975 (100.0%)	1,582,529 (90.90%)	158,446 (9.10%)		1,627,777 (93.50%)	50,397 (2.89%)	62,801 (3.61%)		1,660,704 (95.39%)	80,271 (4.61%)	
Age, years, n (%)											
20–29	170,111 (9.77)	169,570 (10.72)	541 (0.34)		169,765 (10.43)	229 (0.45)	117 (0.19)		169,833 (10.23)	278 (0.35)	
30–39	185,906 (10.68)	184,464 (11.66)	1,442 (0.91)		184,225 (11.32)	771 (1.53)	910 (1.45)		184,528 (11.11)	1,378 (1.72)	
40–49	397,281 (22.82)	385,036 (24.33)	12,245 (7.73)		385,696 (23.69)	5,037 (9.99)	6,548 (10.43)		386,987 (23.30)	10,294 (12.82)	
50–59	233,813 (13.43)	212,851 (13.45)	20,962 (13.23)		216,794 (13.32)	7,323 (14.53)	9,696 (15.44)		218,932 (13.18)	14,881 (18.54)	
60–69	489,256 (28.10)	413,425 (26.12)	75,831 (47.86)		433,466 (26.63)	24,210 (48.04)	31,580 (50.29)		450,606 (27.13)	38,650 (48.15)	
70–79	206,239 (11.85)	166,933 (10.55)	39,306 (24.81)		182,980 (11.24)	10,858 (21.54)	12,401 (19.75)		192,906 (11.62)	13,333 (16.61)	
≥80	58,369 (3.35)	50,250 (3.18)	8,119 (5.12)		54,851 (3.37)	1,969 (3.91)	1,549 (2.47)		56,912 (3.43)	1,457 (1.82)	
Sex, n (%)				<0.01				<0.01			<0.01
Male	834,739 (47.95)	765,494 (48.37)	69,245 (43.70)		780,871 (47.97)	25,082 (49.77)	28,786 (45.84)		803,784 (48.40)	30,955 (38.56)	
Female	906,236 (52.05)	817,035 (51.63)	89,201 (56.30)		846,906 (52.03)	25,315 (50.23)	34,015 (54.16)		856,920 (51.60)	49,316 (61.44)	
Income, n (%)				<0.01				<0.01			<0.01
Rank 1–3	692,465 (39.77)	619,437 (39.14)	73,028 (46.09)		641,763 (39.43)	22,976 (45.59)	27,726 (44.15)		653,866 (39.37)	38,599 (48.09)	
Rank 4–6	470,362 (27.02)	430,599 (27.21)	39,763 (25.10)		441,160 (27.10)	12,771 (25.34)	16,431 (26.16)		450,134 (27.11)	20,228 (25.20)	
Rank 7–10	513,399 (29.49)	468,435 (29.60)	44,964 (28.38)		480,803 (29.54)	14,302 (28.38)	18,294 (29.13)		492,204 (29.64)	21,195 (26.40)	
Medical aid	64,749 (3.72)	64,058 (4.05)	691 (0.44)		64,051 (3.93)	348 (0.69)	350 (0.56)		64,500 (3.88)	249 (0.31)	
CCI, mean (SD)	0.65 (0.92)	0.56 (0.83)	1.54 (1.26)	<0.01	0.56 (0.81)	1.84 (1.37)	2.02 (1.34)	<0.01	0.60 (0.88)	1.59 (1.26)	<0.01
Smoking status, n (%)[a]				<0.01				<0.01			<0.01
Never	562,566 (69.29)	506,474 (68.60)	56,092 (76.29)		525,270 (69.10)	16,425 (71.76)	20,871 (72.45)		530,572 (68.90)	31,994 (76.56)	
Former, <20 years	35,137 (4.33)	32,616 (4.42)	2,541 (3.46)		33,348 (4.39)	859 (3.75)	950 (3.30)		33,590 (4.36)	1,567 (3.75)	
Former, ≥20 years	23,914 (2.95)	20,691 (2.80)	3,223 (4.38)		21,818 (2.87)	990 (4.33)	1,106 (3.84)		22,336 (2.90)	1,578 (3.78)	
Current, <20 PY	123,101 (15.16)	116,559 (15.78)	6,562 (8.92)		117,374 (15.44)	2,567 (11.22)	3,160 (10.97)		119,269 (15.49)	3,832 (9.17)	
Current, ≥20 PY	67,124 (8.27)	62,016 (8.40)	5,108 (6.95)		62,356 (8.20)	2,047 (8.94)	2,721 (9.45)		64,306 (8.35)	2,818 (6.74)	
Alcohol, g/day, n (%)[a]				<0.01				<0.01			<0.01
0–10	650,245 (80.09)	587,231 (79.53)	63,014 (85.70)		607,021 (79.85)	18,915 (82.64)	24,309 (84.38)		614,413 (79.79)	35,832 (85.75)	
10–20	91,683 (11.29)	85,977 (11.64)	5,706 (7.76)		87,351 (11.49)	2,019 (8.82)	2,313 (8.03)		88,432 (11.48)	3,251 (7.78)	
20–30	7,089 (0.87)	6,713 (0.91)	376 (0.51)		6,665 (0.88)	185 (0.81)	239 (0.83)		6,815 (0.88)	274 (0.66)	
30–40	25,827 (3.18)	24,000 (3.25)	1,827 (2.48)		24,389 (3.21)	684 (2.99)	754 (2.62)		24,823 (3.22)	1,004 (2.40)	
≥40	37,018 (4.56)	34,415 (4.66)	2,603 (3.54)		34,470 (4.57)	1,085 (4.74)	1,193 (4.14)		35,590 (4.62)	1,428 (3.42)	
Hypertension, n (%)[a]				<0.01				<0.01			<0.01
Yes	504,321 (62.12)	480,020 (65.01)	24,301 (33.05)		481,162 (63.30)	9,989 (43.64)	13,170 (45.72)		485,936 (63.10)	18,385 (43.99)	
No	307,541 (37.88)	258,316 (34.99)	49,225 (66.95)		279,004 (36.70)	12,899 (56.36)	15,638 (54.28)		284,137 (36.90)	23,404 (56.01)	
BMI, mean (SD)[b]	23.88 (3.07)	23.79 (3.04)	24.82 (3.18)	<0.01	23.82 (3.05)	24.77 (3.13)	24.84 (3.17)	<0.01	23.81 (3.06)	25.18 (2.98)	<0.01

Note: Categorical variables were compared using the χ^2 test, and continuous variables were compared using Student t test (aspirin or statin) or ANOVA (metformin).

Abbreviations: DM, diabetes mellitus; PY, pack-years.

[a]Sample size is 811,862 due to missing values of each independent variable.

[b]Sample size is 811,172 due to missing values of BMI.

Table 2. Total dose of cardiovascular drugs among the study population.

	2002–2003	2004–2005	2006–2007	2008–2009	2010–2011
N	1,740,975	1,740,975	1,698,800	1,652,451	1,606,151
Aspirin					
Never use	1,582,529 (90.90)	1,496,164 (85.94)	1,399,726 (82.39)	1,329,776 (80.47)	1,279,451 (79.66)
Duration of aspirin use, day, *n* (%)					
<182.5	81,515 (4.68)	106,421 (6.11)	102.908 (6.06)	96,772 (5.86)	93,160 (5.80)
182.5–365.0	28,916 (1.66)	38.464 (2.21)	43,379 (2.55)	42.982 (2.60)	42,184 (2.63)
365.0–547.5	20,001 (1.15)	32,342 (1.86)	39,689 (2.34)	41,777 (2.53)	41,849 (2.61)
≥547.5	28,014 (1.61)	67,584 (3.88)	113,098 (6.66)	141,144 (8.54)	149,507 (9.31)
Metformin					
Non-DM	1,627,777 (93.50)	1,589,588 (91.30)	1,523,726 (89.69)	1,458,145 (88.24)	1,397,187 (86.99)
Never use among DM patients	50,397 (2.89)	61,214 (3.52)	61,874 (3.64)	57,673 (3.49)	45,649 (2.97)
cDDD of metformin use, *n* (%)					
<182.5	43,165 (2.48)	56,011 (3.22)	64,985 (3.83)	76,462 (4.63)	85,298 (5.31)
182.5–365.0	14,591 (0.84)	23,920 (1.37)	32,480 (1.91)	39,009 (2.36)	48,259 (3.00)
365.0–547.5	3,898 (0.22)	7,507 (0.43)	10,902 (0.64)	13,713 (0.83)	17,032 (1.06)
≥547.5	1,147 (0.07)	2,735 (0.16)	4,833 (0.28)	7,449 (0.45)	10,726 (0.67)
Statins					
Never use	1,660,704 (95.39)	1,609,299 (92.44)	1,503,551 (88.51)	1,400,497 (84.75)	1,300,613 (80.98)
cDDD of statin use, *n* (%)					
<182.5	66,192 (3.80)	93,331 (5.36)	112,264 (6.61)	128,999 (7.81)	136,440 (8.49)
182.5–365.0	11,407 (0.66)	26,963 (1.55)	48,141 (2.83)	64,584 (3.91)	94,764 (5.90)
365.0–547.5	2,345 (0.13)	8.695 (0.50)	23,946 (1.41)	35,725 (2.16)	39,433 (2.46)
≥547.5	327 (0.02)	2,687 (0.15)	10,898 (0.64)	22,646 (1.37)	34,901 (2.17)

Abbreviation: DM, diabetes mellitus.

Table 3. Associations of cardiovascular drug use with incidence and mortality of gastric cancer in separate analyses of aspirin, metformin, or statin.

	Gastric cancer incidence				Gastric cancer mortality			
	Model 1[a]		Model 2[b]		Model 1[a]		Model 2[b]	
	HR (95% CI)	*P*	HR (95% CI)	*P*	HR (95% CI)	*P*	HR (95% CI)	*P*
Case, *N*	16,843		9,250		8,463		3,206	
Person-years	16,221,786.25		7,783,607.32		16,284,456.7		7,819,859.90	
Crude IRs (per 10^5 person-year)	103.83		118.84		51.97		41.00	
Duration of aspirin use, day								
Never use	1.00 (Reference)		1.00 (Reference)		1.00 (Reference)		1.00 (Reference)	
<182.5	0.97 (0.91–1.03)	0.32	0.96 (0.89–1.04)	0.34	1.08 (1.01–1.17)	0.04	1.19 (1.06–1.34)	<0.01
182.5–365.0	0.87 (0.79–0.95)	<0.01	0.85 (0.74–0.96)	0.01	0.96 (0.86–1.08)	0.53	0.91 (0.74–1.10)	0.32
365.0–547.5	0.84 (0.76–0.93)	<0.01	0.78 (0.68–0.90)	<0.01	0.96 (0.85–1.09)	0.53	1.00 (0.82–1.21)	0.98
≥547.5	0.94 (0.89–0.99)	0.03	0.89 (0.82–0.96)	<0.01	0.68 (0.63–0.74)	<0.01	0.62 (0.54–0.72)	<0.01
P_{trend}	<0.01		<0.01		<0.01		<0.01	
cDDD of metformin use								
Non-DM	1.00 (Reference)		1.00 (Reference)		1.00 (Reference)		1.00 (Reference)	
DM, never use	1.18 (1.10–1.27)	<0.01	1.23 (1.11–1.36)	<0.01	1.69 (1.55–1.83)	<0.01	2.15 (1.89–2.45)	<0.01
<182.5	1.19 (1.11–1.28)	<0.01	1.11 (1.01–1.22)	0.03	1.33 (1.22–1.46)	<0.01	1.42 (1.23–1.64)	<0.01
182.5–365.0	1.25 (1.14–1.37)	<0.01	1.26 (1.12–1.43)	<0.01	1.20 (1.06–1.37)	0.010	1.43 (1.18–1.75)	<0.01
365.0–547.5	1.18 (1.01–1.38)	0.04	1.23 (0.99–1.52)	0.05	1.00 (0.78–1.27)	0.98	1.13 (0.77–1.64)	0.53
≥547.5	1.25 (1.01–1.55)	0.04	1.11 (0.82–1.50)	0.50	0.82 (0.57–1.19)	0.30	0.67 (0.35–1.29)	0.23
P_{trend}[c]	0.39		0.96		<0.01		<0.01	
cDDD of statin use								
Never use	1.00 (Reference)		1.00 (Reference)		1.00 (Reference)		1.00 (Reference)	
<182.5	1.00 (0.94–1.06)	1.00	0.92 (0.85–1.00)	0.05	0.71 (0.64–0.78)	<0.01	0.70 (0.60–0.82)	<0.01
182.5–365.0	1.07 (0.99–1.17)	0.09	1.02 (0.91–1.14)	0.75	0.74 (0.65–0.84)	<0.01	0.82 (0.67–0.99)	0.04
365.0–547.5	1.12 (1.00–1.26)	0.05	1.07 (0.91–1.25)	0.42	0.78 (0.65–0.93)	0.01	0.69 (0.51–0.94)	0.02
≥547.5	1.07 (0.93–1.23)	0.35	1.04 (0.86–1.26)	0.71	0.70 (0.56–0.88)	<0.01	0.58 (0.39–0.86)	0.01
P_{trend}	0.02		0.83		<0.01		<0.01	

Abbreviation: DM, diabetes mellitus.
[a]Model 1: adjusted for age (5-year group), sex, income, and CCI (continuous).
[b]Model 2: adjusted for age (5-year group), sex, income, CCI (continuous), BMI (continuous), smoking status, alcohol consumption, and hypertension.
[c]P_{trend} was calculated among patients with diabetes only.

Table 4. Associations of cardiovascular drug use with incidence and mortality of gastric cancer in concurrent analyses of aspirin, metformin, or statin.

	Gastric cancer incidence				Gastric cancer mortality			
	Model 1[a]		Model 2[b]		Model 1[a]		Model 2[b]	
	HR (95% CI)	P	HR (95% CI)	P	HR (95% CI)	P	HR (95% CI)	P
Duration of aspirin use, day								
Never use	1.00 (Reference)		1.00 (Reference)		1.00 (Reference)		1.00 (Reference)	
<182.5	0.95 (0.89–1.01)	0.08	0.95 (0.88–1.04)	0.26	1.09 (1.02–1.18)	0.02	1.20 (1.07–1.35)	<0.01
182.5–365.0	0.83 (0.76–0.92)	<0.01	0.83 (0.73–0.94)	<0.01	0.97 (0.86–1.10)	0.65	0.91 (0.74–1.10)	0.32
365.0–547.5	0.80 (0.73–0.89)	<0.01	0.76 (0.66–0.87)	<0.01	0.97 (0.86–1.10)	0.65	0.99 (0.82–1.21)	0.96
≥547.5	0.89 (0.84–0.94)	<0.01	0.85 (0.78–0.92)	<0.01	0.69 (0.63–0.75)	<0.01	0.62 (0.54–0.72)	<0.01
P_{trend}	<0.01		<0.01		<0.01		<0.01	
cDDD of metformin use								
Non-DM	1.00 (Reference)		1.00 (Reference)		1.00 (Reference)		1.00 (Reference)	
DM, never use	1.20 (1.11–1.29)	<0.01	1.25 (1.13–1.39)	<0.01	1.81 (1.66–1.97)	<0.01	2.29 (2.01–2.61)	<0.01
<182.5	1.21 (1.13–1.30)	<0.01	1.14 (1.04–1.26)	0.01	1.45 (1.32–1.58)	<0.01	1.52 (1.32–1.76)	<0.01
182.5–365.0	1.28 (1.16–1.40)	<0.01	1.31 (1.15–1.48)	<0.01	1.34 (1.18–1.53)	<0.01	1.60 (1.31–1.95)	<0.01
365.0–547.5	1.20 (1.03–1.41)	0.02	1.27 (1.03–1.58)	0.03	1.13 (0.89–1.44)	0.32	1.28 (0.88–1.86)	0.20
≥547.5	1.27 (1.03–1.57)	0.03	1.15 (0.85–1.55)	0.37	0.95 (0.65–1.37)	0.77	0.78 (0.40–1.50)	0.45
P_{trend}[c]	0.24		0.79		<0.01		<0.01	
cDDD of statin use								
Never use	1.00 (Reference)		1.00 (Reference)		1.00 (Reference)		1.00 (Reference)	
<182.5	1.00 (0.94–1.07)	0.96	0.93 (0.86–1.01)	0.08	0.67 (0.61–0.74)	<0.01	0.66 (0.56–0.77)	<0.01
182.5–365.0	1.08 (0.99–1.18)	0.06	1.04 (0.93–1.17)	0.47	0.73 (0.64–0.84)	<0.01	0.82 (0.67–0.99)	0.04
365.0–547.5	1.13 (1.00–1.27)	0.04	1.09 (0.93–1.28)	0.29	0.80 (0.67–0.96)	0.01	0.70 (0.52–0.96)	0.03
≥547.5	1.08 (0.94–1.25)	0.30	1.07 (0.88–1.30)	0.50	0.74 (0.59–0.93)	0.01	0.62 (0.41–0.92)	0.02
P_{trend}	0.02		0.46		<0.01		<0.01	

Abbreviations: CVD, cardiovascular disease; DM, diabetes mellitus.
[a]Model 1: adjusted for age (5-year group), sex, income, CCI (continuous), and concomitant use of other CVD drugs.
[b]Model 2: adjusted for age (5-year group), sex, income, CCI (continuous), BMI (continuous), smoking status, alcohol consumption, hypertension, and concomitant use of other CVD drugs.
[c]P_{trend} was calculated among patients with diabetes only.

Table 5. Associations of metformin use with incidence and mortality of gastric cancer in patients with diabetes.

	Gastric cancer incidence				Gastric cancer mortality			
	Model 1[a]		Model 2[b]		Model 1[a]		Model 2[b]	
	HR (95% CI)	P	HR (95% CI)	P	HR (95% CI)	P	HR (95% CI)	P
Case, N	2,449		1,287		1,482		614	
Person-years	1,529,524.25		740,447.96		1,540,026.80		746,205.82	
Crude IRs (per 10^5 person-year)	160.12		173.81		86.23		82.28	
Separate analyses of aspirin, metformin, or statin								
cDDD of metformin use								
DM, never use	1.00 (Reference)		1.00 (Reference)		1.00 (Reference)		1.00 (Reference)	
<182.5	0.99 (0.90–1.09)	0.89	0.91 (0.79–1.04)	0.15	0.76 (0.68–0.86)	<0.01	0.64 (0.54–0.77)	<0.01
182.5–365.0	1.06 (0.95–1.19)	0.29	1.03 (0.88–1.21)	0.87	0.68 (0.59–0.79)	<0.01	0.65 (0.51–0.81)	<0.01
365.0–547.5	1.00 (0.84–1.19)	0.97	1.00 (0.80–1.27)	0.97	0.56 (0.44–0.73)	<0.01	0.51 (0.34–0.75)	<0.01
≥547.5	1.07 (0.86–1.34)	0.54	0.91 (0.66–1.25)	0.56	0.46 (0.31–0.67)	<0.01	0.30 (0.15–0.58)	<0.01
P_{trend}	0.39		0.96		<0.01		<0.01	
Concurrent analyses of aspirin, metformin, or statin								
cDDD of metformin use								
DM, never use	1.00 (Reference)		1.00 (Reference)		1.00 (Reference)		1.00 (Reference)	
<182.5	1.00 (0.91–1.10)	0.95	0.92 (0.80–1.05)	0.22	0.76 (0.68–0.86)	<0.01	0.65 (0.54–0.78)	<0.01
182.5–365.0	1.08 (0.97–1.21)	0.18	1.05 (0.90–1.23)	0.53	0.71 (0.61–0.82)	<0.01	0.67 (0.54–0.85)	<0.01
365.0–547.5	1.02 (0.86–1.22)	0.79	1.03 (0.81–1.29)	0.83	0.59 (0.46–0.77)	<0.01	0.54 (0.36–0.80)	<0.01
≥547.5	1.09 (0.87–1.37)	0.44	0.93 (0.67–1.27)	0.63	0.49 (0.34–0.72)	<0.01	0.32 (0.17–0.63)	<0.01
P_{trend}	0.24		0.79		<0.01		<0.01	

Abbreviations: CVD, cardiovascular disease, DM, diabetes mellitus.
[a]Model 1: adjusted for age (5-year group), sex, income, CCI (continuous), and concomitant use of other CVD drugs.
[b]Model 2: adjusted for age (5-year group), sex, income, CCI (continuous), BMI (continuous), smoking status, alcohol consumption, hypertension, and concomitant use of other CVD drugs.

aspirin, an antiplatelet agent to prevent cardiovascular diseases, is a COX-1 and COX-2 inhibitor, this drug has potential antineoplastic effects against gastric cancer by blocking the COX pathway and by inducing apoptosis (9–12). Consistent with previous studies, our results support the hypothesis that aspirin exerts chemopreventive effects against gastric cancer incidence in a dose-dependent manner (27, 28, 34). The aHRs of gastric cancer incidence among aspirin users in our study were higher than estimates from a previous meta-analysis (RR, 0.75; 95% CI, 0.65–0.86; ref. 21). This was probably because low-dose aspirin can be purchased without a prescription in Korea and was quite widely used in the early 2000s (42), so low-dose aspirin users might be underestimated in our study. Our findings also suggest that gastric cancer mortality decreases with increasing duration of aspirin use. While gastric cancer incidence was reduced by 16% in our results, gastric cancer mortality decreased up to 40% in aspirin-user groups. Possible reasons for the lower gastric cancer mortality compared with non-aspirin users are (i) lower cancer incidence due to aspirin use and (ii) potential survival benefits of aspirin in patients even after diagnosis with gastric cancer.

Multiple previous studies suggested that diabetes is associated with higher risks of gastric cancer incidence (34, 43, 44) and mortality (44), which is consistent with our finding that patients with diabetes were at elevated risks for gastric cancer incidence and mortality compared with nondiabetic patients. Metformin has been shown to inhibit proliferation of gastric cancer cell (15) and promote apoptosis, leading to anticancer effects (13, 14). Previous meta-analyses studies reported the chemopreventive effects of metformin use on gastric cancer incidence (30) and survival benefits in patients with diabetes treated with metformin therapy (36). In a previous study with patients with type 2 diabetes, gastric cancer risk was marginally lowered with regular metformin use (aHR, 0.73; 95% CI, 0.53–1.01), and the decrease became significant with metformin use for ≥3 years (aHR, 0.57; 95% CI, 0.37–0.87) in the insulin nonuser group (29). However, we did not find an association between metformin use and gastric cancer incidence even in patients with diabetes in this study. This discrepancy is may be because previous studies did not consider concomitant use of other cardiovascular drugs (29, 30) or because medical conditions seen in patients with diabetes, such as diabetes duration or disease severity, were not considered in this study. On the other hand, metformin use among patients with diabetes showed linear dose-response effects on gastric cancer mortality in this study. This finding is consistent with previous study conducted in patients with gastric cancer, reporting that longer cumulative duration of metformin use was associated with lower risks of recurrence and gastric cancer–specific and all-cause mortality (i.e., HR, 0.86–0.87 for each outcome, with six additional cumulative months of metformin use after gastrectomy; ref. 35).

Statins are widely used to treat hypercholesterolemia. The basic mechanism of the anticancer effect of statins is inhibition of the rate-limiting step of the mevalonate pathway (16, 17).

The mevalonate pathway produces mevalonic acid, which acts as a precursor to produce multiple end-products, and some of these products, such as *Ras* and *Rho*, regulate various signal processes related to cellular proliferation, angiogenesis, and antiapoptosis (16, 45). However, in our study, statin use was not associated with reduction of gastric cancer incidence. This was not consistent with results from a previous meta-analysis reporting a dose-response chemopreventive effect of statin use on reduction of gastric cancer risk [adjusted OR (aOR), 0.35; 95% CI, 0.16–0.76 for long duration of use vs. aOR, 0.73; 95% CI, 0.51–1.05 for short duration of use; ref. 33). However, although the meta-analysis of all studies suggested positive associations, results from subgroup analyses varied, depending on study design and setting (33). Also, because concurrent use of aspirin and metformin was not considered in previous studies, this could be a reason for the discrepancy seen. Thus, further research is needed to determine the chemopreventive effects of statin use against gastric cancer. In contrast, statin use was associated with lower gastric mortality even at cDDD < 182.5 in this study. Better survival outcomes among patients with gastric cancer with statin use were previously reported in a small case–control study from Korea (34) and in cancer registry studies from Denmark (24) and England–Scotland (46). Given that gastric cancer incidence was not reduced with statin use, it is probable that the anticancer effects of statin use are more beneficial for patients with gastric cancer compared with the general population.

One notable distinction of our study is simultaneous inclusion of aspirin, metformin, and statin use in a single analysis model. In clinical practice, cardiovascular drugs (aspirin, metformin, and statin) are often prescribed together. However, many previous studies about anticancer effects of cardiovascular drugs have been conducted without considering concurrent use of other drugs. Because the biological mechanisms of cardiovascular drugs may interact with each other to create positive or negative synergetic effects on gastric cancer, effects of these drugs would be over- or underestimated without considering their simultaneous administration. In this study, tendencies for anticancer effects against gastric cancer remained after adjustments for other drug use. However, the degree of antineoplastic effects in each cardiovascular drug was slightly attenuated when the models were simultaneously adjusted for use of other drugs. Such results suggest that estimates from previous studies that did not account for other cardiovascular drug use might have overestimated preventive effects, especially when the results showed marginal effects.

There are several limitations of our study. First, as we used secondary data–based claims reimbursement data, we were unable to take into account clinical information, such as stages, histologic types, and anatomic locations of gastric cancer, and other known risk factors of gastric cancer, such as *Helicobacter pylori* infection and medical history of gastric ulcer or other precancerous disease. Further studies considering theses additional factors are needed to determine clinical applications of cardiovascular drugs to reduce risks of gastric

cancer. Second, for analysis of metformin use, it is important to consider clinical details of diabetes, such as disease severity and diabetes duration, which were not considered in this study due to the nature of reimbursement data. Third, we may have underestimated gastric cancer incidence because we identified it using a disease code and reimbursement data representing cancer treatment. Thus, untreated gastric cancer could not be counted as gastric cancer in this study. However, because universal health coverage is provided to almost all Koreans, and the proportion of early-gastric cancer among patients with gastric cancer is high due to gastric cancer screening provided by the National Cancer Screening Program every 2 years, untreated gastric cancer may not be common unless people are very old or have other serious health problems. Thus, there is no reason to believe that untreated gastric cancer is generally common among cardiovascular drug users. Fourth, aspirin can be purchased over the counter without a prescription. Thus, aspirin use might be underestimated in this study. Finally, regarding mortality, we may have overestimated the anticancer effects due to screening effects. It is possible that cardiovascular drug users have more frequent contact with health care professionals and receive more cancer screening examinations than the general population (47, 48). In this case, they are likely to be diagnosed at an early stage of gastric cancer, leading to lower mortality.

In summary, the results of this study suggest that aspirin use was independently associated with reduced incidence and mortality of gastric cancer in the general population, but metformin or statin use was only associated with a reduction of gastric cancer mortality in patients with diabetes and in the general population in a dose-response manner, respectively. Further studies are needed to determine clinical applications of these cardiovascular drugs as chemopreventive agents in public health and clinical practice.

Authors' Disclosures

No disclosures were reported.

Authors' Contributions

M.H. Cho: Formal analysis, writing-original draft, writing-review and editing. **T.G. Yoo:** Conceptualization, formal analysis, writing-original draft. **S.-M. Jeong:** Conceptualization. **D.W. Shin:** Conceptualization, supervision, writing-review and editing.

Acknowledgments

References

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394–424.
2. Rawla P, Barsouk A. Epidemiology of gastric cancer: global trends, risk factors and prevention. Prz Gastroenterol 2019;14:26–38.
3. Jung KW, Won YJ, Kong HJ, Lee ES. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2016. Cancer Res Treat 2019;51:417–30.
4. Deaton C, Froelicher ES, Wu LH, Ho C, Shishani K, Jaarsma T. The global burden of cardiovascular disease. Eur J Cardiovacular Nur 2011; 10:S5–S13.
5. Koene RJ, Prizment AE, Blaes A, Konety SH. Shared risk factors in cardiovascular disease and cancer. Circulation 2016;133:1104–14.
6. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420: 860–7.
7. Libby P. Inflammation and cardiovascular disease mechanisms. Am J Clin Nutr 2006;83:456S–460S.
8. Aggarwal BB, Vijayalekshmi RV, Sung B. Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin Cancer Res 2009;15:425–30.
9. Shaheen NJ, Straus WL, Sandler RS. Chemoprevention of gastrointestinal malignancies with nonsteroidal antiinflammatory drugs: a review. Cancer 2002;94:950–63.
10. Redlak MJ, Power JJ, Miller TA. Prevention of Deoxycholate-induced gastric apoptosis by aspirin: roles of NF-κB and PKC signaling. J Surg Res 2008;145:66–73.
11. Cheng J, Fan XM. Role of cyclooxygenase-2 in gastric cancer development and progression. World J Gastroenterol 2013;19:7361–8.
12. Wong B, Zhu G, Lam S. Aspirin induced apoptosis in gastric cancer cells. Biomed Pharmacother 1999;53:315–8.
13. Han G, Gong H, Wang Y, Guo S, Liu K. AMPK/mTOR-mediated inhibition of survivin partly contributes to metformin-induced apoptosis in human gastric cancer cell. Cancer Biol Ther 2015; 16:77–87.
14. Chen G, Feng W, Zhang S, Bian K, Yang Y, Fang C, et al. Metformin inhibits gastric cancer via the inhibition of HIF1α/PKM2 signaling. Am J Cancer Res 2015;5:1423–34.
15. Kato K, Gong J, Iwama H, Kitanaka A, Tani J, Miyoshi H, et al. The antidiabetic drug metformin inhibits gastric cancer cell proliferation *in vitro* and *in vivo*. Mol Cancer Ther 2012;11: 549–60.
16. Demierre M-F, Higgins PD, Gruber SB, Hawk E, Lippman SM. Statins and cancer prevention. Nat Rev Cancer 2005;5:930–42.
17. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990;343:425–30.
18. Algra AM, Rothwell PM. Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol 2012;13: 518–27.
19. Cook NR, Lee IM, Gaziano JM, Gordon D, Ridker PM, Manson JE, et al. Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA 2005; 294:47–55.
20. Rothwell PM, Fowkes FGR, Belch JF, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 2011;377:31–41.

21. Qiao Y, Yang T, Gan Y, Li W, Wang C, Gong Y, et al. Associations between aspirin use and the risk of cancers: a meta-analysis of observational studies. BMC Cancer 2018;18:288.

22. Noto H, Goto A, Tsujimoto T, Noda M. Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PLoS One 2012;7:e33411.

23. Franciosi M, Lucisano G, Lapice E, Strippoli GF, Pellegrini F, Nicolucci A. Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review. PLoS One 2013;8:e71583.

24. Nielsen SF, Nordestgaard BG, Bojesen SE. Statin use and reduced cancer-related mortality. N Engl J Med 2012;367:1792–802.

25. Browning DR, Martin RM. Statins and risk of cancer: a systematic review and metaanalysis. Int J Cancer 2007;120:833–43.

26. You S, Sun G, Yao Q, Wan Z, Huang X. Statin use and risk of gastrointestinal cancer: a meta-analysis of cohort studies. Int J Clin Exp Med 2018;11:1437–47.

27. Kim YI, Kim SY, Kim JH, Lee JH, KIM YW, Ryu LW, et al. Long-term low-dose aspirin use reduces gastric cancer incidence: a nationwide cohort study. Cancer Res Treat 2016;48: 798–805.

28. Kim M, Chang J, Kim WJ, Banerjee S, Park SM. Cumulative dose threshold for the chemopreventive effect of aspirin against gastric cancer. Am J Gastroenterol 2018;113:845–54.

29. Kim YI, Kim S, Cho SJ, Park JH, Choi IJ, Lee YJ, et al. Long-term metformin use reduces gastric cancer risk in type 2 diabetics without insulin treatment: a nationwide cohort study. Aliment Pharmacol Ther 2014;39:854–63.

30. Zhou XL, Xue WH, Ding XF, Li LF, Dou MM, Zhang WJ, et al. Association between metformin and the risk of gastric cancer in patients with type 2 diabetes mellitus: a meta-analysis of cohort studies. Oncotarget 2017;8:55622–31.

31. Lee J, Lee SH, Hur KY, Woo SY, Kim SW, Kamg WK. Statins and the risk of gastric cancer in diabetes patients. BMC Cancer 2012; 12:596.

32. Chiu HF, Ho SC, Chang CC, Wu TN, Yang CY. Statins are associated with a reduced risk of gastric cancer: a population-based case–control study. Am J Gastroenterol 2011;106:2098–103.

33. Singh P, Singh S. Statins are associated with reduced risk of gastric cancer: a systematic review and meta-analysis. Ann Oncol 2013;24: 1721–30.

34. Tseng CH, Tseng FH. Diabetes and gastric cancer: the potential links. World J Gastroenterol 2014;20:1701–11.

35. Lee C, Jung M, Jung I, Heo SJ, Jeong YH, An JY, et al. Cumulative metformin use and its impact on survival in gastric cancer patients after gastrectomy. Ann Surg 2016;263:96–102.

36. Li P, Zhang C, Gao P, Chen X, Ma B, Yu D, et al. Metformin use and its effect on gastric cancer in patients with type 2 diabetes: a systematic review of observational studies. Oncol Lett 2018;15:1191–9.

37. Seong SC, Kim YY, Khang YH, Kim HC, Pakr JH, Jang HJ, et al. Data resource profile: the national health information database of the National Health Insurance Service in South Korea. Int J Epidemiol 2016;46:799–800.

38. Seong SC, Kim YY, Park SK, Khang YH, Kim HC, Park JH, et al. Cohort profile: the National Health Insurance Service-National Health Screening Cohort (NHIS-HEALS) in Korea. BMJ Open 2017;7: e016640.

39. World Health Organization. The anatomical therapeutic chemical classification system with defined daily doses (ATC/DDD). Available from: https://www.whocc.no/atc_ddd_index/

40. Clapp RW, Jacobs MM, Loechler EL. Environmental and occupational causes of cancer: new evidence 2005–2007. Rev Environ Health 2008; 23:1–38.

41. Lim HY, Joo HJ, Choi JH, Yi JW, Yang MS, Cho DY, et al. Increased expression of cyclooxygenase-2 protein in human gastric carcinoma. Clin Cancer Res 2000;6:519–25.

42. Pearson TA, Blair SN, Daniels SR, Eckel RH, Fair JM, Fortmann SP, et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. Circulation 2002;106:388–91.

43. Ge Z, Ben Q, Qian J, Wang Y, Li Y. Diabetes mellitus and risk of gastric cancer: a systematic review and meta-analysis of observational studies. Eur J Gastroenterol Hepatol 2011;23:1127–35.

44. Tian T, Zhang L, Ma X, Zhou J, Shen J. Diabetes mellitus and incidence and mortality of gastric cancer: a meta-analysis. Exp Clin Endocrinol Diabetes 2012;120:217–23.

45. Kubatka P, Kruzliak P, Rotrekl V, Jelinkova S, Mladosievicova B. Statins in oncological research: from experimental studies to clinical practice. Crit Rev Oncol Hemat 2014;92:296–311.

46. Spence AD, Busby J, Hughes CM, Cohnston BT, Coleman HG, Cardwell CR. Statin use and survival in patients with gastric cancer in two independent population-based cohorts. Pharmacoepidemiol Drug Saf 2019;28:460–70.

47. Myong JP, Shin J, Kim S. Factors associated with participation in colorectal cancer screening in Korea: the Fourth Korean National Health and Nutrition Examination Survey (KNHANES IV). Int J Colorectal Dis 2012;27:1061–9.

48. Kwak MS, Park EC, Bang JY, Sung NY, Lee JY, Choi KS. Factors associated with cancer screening participation, Korea. J Prev Med Public Health 2005;38:473–81.